The input will help the MHRA to effectively regulate new AI technologies in the NHS and wider healthcare and ensure they support innovation and meet the needs of patients and families ... MHRA in 2026.
The MHRA, as the regulator for medicines, medical devices, and blood products, is continuing to consider what the regulatory rules should be for AI as a medical device ... MHRA - Medicines and Healthcare ...
MHRAForeword. The MHRA is uniquely positioned to shape a system where fairness is built into medicines and devices from the start ...To do this, I see three essential dimensions where the MHRA can have transformational impact.
) Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma ...Agency in the United Kingdom (MHRA) for marketing.
Instead, the MHRA advises anyone taking warfarin to keep their intake of vitamin-K-rich foods consistent, especially during the festive period when diets often change ... Dr StephanieMillican from the MHRA's Safety and Surveillance team, said..
Dr Ravina Barrett, Self Medication and Reclassification Team Lead at the MHRA, said. ... As with all medicines, the MHRA will continue to monitor the safety and effectiveness of Pirinase Allergy 0.05% w/w NasalSpray.
Depemokimab has been approved, via the MHRA's national assessment procedure, for patients with these conditions whose symptoms remain inadequately controlled despite treatment with standard of care, including surgery in the case of CRSwNP.
Lawrence Tallon, Chief Executive of the MHRA, said. ... "Building on our strong collaborative work through the Access Consortium, both HSA and MHRA will co-create transparent, science-based approaches to assess breakthrough technologies.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 December 2025) approved the medicine mirdametinib (Ezmekly) for the treatment of plexiform neurofibromas in adults and adolescents.